IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives

IRVINE, Calif., Dec. 31 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced that as part of the Company's recent decision to evaluate strategic alternatives, the Company initiated discussions with sanofi-aventis. Following this, sanofi-aventis has notified the Company o...

IDM Pharma Reports First Quarter Financial Results

...ollaboration agreement with sanofi-aventis for the uvidem program. As a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem were recognized after the first quarter of 2008. ...

IDM Pharma Reports First Quarter Financial Results

... a result of sanofi-aventis' decision to terminate its participation in the uvidem development program in December 2007, no further such revenues related to uvidem will be recognized after this quarter. Research and development (R&D) exp...

IDM Pharma Reports 2007 Financial Results

...ult of the decision by sanofi-aventis to terminate its participation in the uvidem development program in December 2007. Cash and cash equivalents was $28.4 m...fi-aventis' decision in December 2007 to terminate its participation in the uvidem development program. Interest income increased to $0.4 million for the th...

IDM Pharma Reports Third Quarter 2007 Financial Results

...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...due to an increase in development costs related to uvidem clinical trials, which are reimbursed by sanofi-av...6. The spending related to clinical development of uvidem and clinical development, regulatory filings and m...

IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial

... IDM Pharma, Inc. today presented preliminary results from a Phase II uvidem (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and induction of immune respon...

UVIDEM in Medical Technology

IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company

...Updates UVIDEM(R) The next planned step in the uvidem development program is a Phase 2, open-label, randomized study of uvidem designed to evaluate patients with in-transient or...elanoma in the next 60 days. Patients will receive uvidem or...

IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients

...ated results showed that the investigational agent uvidem showed evidence of clinical activity and induction...recognized antigens after vaccination with uvidem were gp100 and MAGE. -- uvidem was well tolerated with only one possibly related ...

IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting

...annual meeting in Chicago on June 1-5 2007. uvidem presentation details: -- "Clinical and immu...gned to assess the safety and clinical activity of uvidem in patients with stage III or IV melanoma with mea...atient enrolled in March 2006. About UVIDEM(R) uvidem is a therapeutic specific immunostimulant develope...

IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial

... - Results show uvidem was well-tolerated with signs of durable disease c...inical trial (DC-MEL-202). The results showed that uvidem was well tolerated with evidence of efficacy and i...arance of anti-TAA specific CD8+ T cells. -- uvidem was well tolerated with toxicity limited to mild e...

UVIDEM in Biological Technology

IDM Pharma Reports 2008 Financial Results

...is' decision to terminate its participation in the uvidem development program in December 2007, we will not ... reduction in spending on MEPACT (mifamurtide) and uvidem development, as well as reductions associated with...ecember 2007 to terminate its participation in the uvidem development program. The $3.5 million includes $3...

IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development

...ical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including uvidem and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where...